Tolvaptan phosphate

Tolvaptan phosphate is a drug used for the treatment of cardiac edema. It is a prodrug of tolvaptan,^[1][2] formulated as the salt tolvaptan sodium phosphate, for intravenous administration. Tolvaptan phosphate is converted into the active drug tolvaptan in the human body following administration.

Trade namesSamtasu

Other namesTolvaptan sodium phosphate; OPC-61815

CAS Number

• 942619-74-1

PubChem CID

• 146035877

Quick facts Clinical data, Trade names ...

Tolvaptan phosphate

Clinical data
Trade names	Samtasu
Other names	Tolvaptan sodium phosphate; OPC-61815
Identifiers
IUPAC name [(5R)-7-Chloro-1-[2-methyl-4-[(2-methylbenzoyl)amino]benzoyl]-2,3,4,5-tetrahydro-1-benzazepin-5-yl] dihydrogen phosphate
CAS Number	942619-74-1
PubChem CID	146035877
ChemSpider	17342600
UNII	Y4P6WS9QVF
KEGG	D11659
Chemical and physical data
Formula	C26H26ClN2O6P
Molar mass	528.93 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1=CC=CC=C1C(=O)NC2=CC(=C(C=C2)C(=O)N3CCCC(C4=C3C=CC(=C4)Cl)OP(=O)(O)O)C
InChI InChI=1S/C26H26ClN2O6P/c1-16-6-3-4-7-20(16)25(30)28-19-10-11-21(17(2)14-19)26(31)29-13-5-8-24(35-36(32,33)34)22-15-18(27)9-12-23(22)29/h3-4,6-7,9-12,14-15,24H,5,8,13H2,1-2H3,(H,28,30)(H2,32,33,34)/t24-/m1/s1 Key:XTCFGVRVASPRTK-XMMPIXPASA-N

Close

It was developed by Otsuka Pharmaceutical Co. and was approved for use in Japan in 2022.^[3]